5-day vinblastine infusion for pancreatic adenocarcinoma. A phase II Southwest Oncology Group study

Invest New Drugs. 1990 May;8(2):205-6. doi: 10.1007/BF00177261.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Agranulocytosis / chemically induced
  • Drug Evaluation
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Pancreatic Neoplasms / drug therapy*
  • Vinblastine / administration & dosage
  • Vinblastine / adverse effects
  • Vinblastine / therapeutic use*

Substances

  • Vinblastine